A new unique gentle method for easier wound debridement

Facilitates gentle removal through softening of devitalized/necrotic tissue for easier debridement. Based on our experience from removing de-vitalized tissue for caries removal we have now developed a new innovative solution for wound debridement – ChloraSolv.

ChloraSolv is based on a Swedish innovation, which utilizes RLS Global’s unique buffered hypochlorite technology to debride and clean wounds to support the natural wound healing process. Clinical data has shown that ChloraSolv has unique properties with regards to infected chronic diabetic foot ulcers, hence allowing for a more effective healing process.

In Europe, almost four million patients are treated for diabetes-related foot ulcers every year. There is a significant unmet medical need for new, effective treatments. Chronic wounds often take a long time to heal, or do not heal at all. The incidence of diabetic foot ulcers continues to grow in line with the increasing prevalence of diabetes across Europe and the world.

Hard to heal wounds that are difficult to heal is a serious and costly complication of underlying diseases such as diabetes, venous insufficiency or injuries to the skin such as pressure ulcers. Patients suffering from these wounds often experience pain, bad smell, decreased mobility and other problems which seriously affecting the quality of life.

Our overall goal is to provide a gentle and effective debridement method that results in improved wound care for healthcare professionals reducing the suffering for patients and the overall cost for the society in treating complicated wounds.

ChloraSolv – a valuable addition in the treatment of infected chronic diabetic foot ulcers providing non-surgical debridement

ChloraSolv has been evaluated on infected chronic diabetic foot ulcers in an open randomized controlled study where safety and tolerability were assessed as well as a beneficial outcome on wound size reduction and wound closure.
There was an early onset of wound size reduction within the first 7 weeks compared to standard treatment i.e sharp debridement as well as wound healing. 7 patients had totally closed wounds after 12 weeks compared to 3 in the standard treatment group.

How does it work?

ChloraSolv is based on a unique buffered gel technology consisting of a two component system, a gel containing amino acids and a solution containing 0.9% sodium hypochlorite. The components are mixed in situ forming a gel that is directly applied on the wound in need for debridement, in order to provide a system designed to maintain an alkaline environment during the application time.

ChloraSolv provides a moist alkaline pH environment that softens and dissolves necrotic tissue and makes it easy to remove by using a blunt instrument and facilitates removal of necrotic tissue preserving healthy, viable tissue during debridement.

Easy to use in primary care settings and in patients’ homes by healthcare professionals – only requires a short application time to enable an efficient cleaning procedure.

ChloraSolv consists of two solutions provided in a double syringe. The solutions are mixed to form a gel at the time of use. The gel is applied on the wound bed and allowed to act for 2 minutes to soften the devitalized tissue. A blunt instrument is then used to help in the mechanical removal devitalized tissue from the application site. The procedure is finished with a second application of the gel directly onto the wound area to completely clean the wound bed.

Using ChloraSolv

ChloraSolv consists of two solutions provided in a double syringe. The solutions are mixed to form a gel at the time of use. The gel is applied on the wound bed and allowed to act for 2 minutes to soften the devitalized tissue. A blunt instrument is then used to help in the mechanical removal devitalized tissue from the application site. Finish the procedure with a second application of the gel directly onto the wound area to completely clean the wound bed.

1. Bergqvist K, Almhojd U, Herrmann I, Eliasson B. The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial. Clin Diabetes Endocrinol. 2016;2:6.